As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

Advances in stem cell biology and immune cell engineering bring diabetes cell therapies closer to reality.

Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...

Qureator, a leading AI-powered human disease model company, today announced the appointment of Dr. Branka Mitrovic as its new Chief Scientific Officer (CSO). Dr. Mitrovic brings extensive experience ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Goldman Sachs initiated coverage of Sionna Therapeutics (SION) with an Early-Stage Biotech designation. Lead assets SION-719 and SION-451 are ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Neumora Therapeutics, Inc. (NMRA – Research ...